Can Lannett Company, Inc.’s Tomorrow Be Different? Option Trader Are Very Bullish

 Can Lannett Company, Inc.'s Tomorrow Be Different? Option Trader Are Very Bullish

In today’s session Lannett Company, Inc. (LCI) registered an unusually high (530) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious LCI increase. With 530 contracts traded and 3224 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: LCI161118C00022500 closed last at: $1.1 or 15.4% down. About 341,105 shares traded hands. Lannett Company, Inc. (NYSE:LCI) has risen 19.80% since March 29, 2016 and is uptrending. It has outperformed by 16.33% the S&P500.

Lannett Company, Inc. (NYSE:LCI) Ratings Coverage

Out of 8 analysts covering Lannett (NYSE:LCI), 6 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 75% are positive. $70 is the highest target while $3 is the lowest. The $42.07 average target is 91.66% above today’s ($21.95) stock price. Lannett has been the topic of 20 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The company was maintained on Thursday, March 24 by Roth Capital. As per Thursday, February 4, the company rating was upgraded by Craig Hallum. Zacks upgraded Lannett Company, Inc. (NYSE:LCI) on Monday, September 7 to “Strong-Buy” rating. As per Thursday, September 3, the company rating was maintained by Roth Capital. On Wednesday, June 29 the stock rating was initiated by Deutsche Bank with “Hold”. Raymond James maintained Lannett Company, Inc. (NYSE:LCI) on Wednesday, August 24 with “Outperform” rating. The rating was downgraded by Craig Hallum to “Hold” on Thursday, November 5. As per Thursday, March 24, the company rating was downgraded by Canaccord Genuity. TH Capital maintained it with “Buy” rating and $68.0 target price in Thursday, September 3 report. Craig Hallum maintained the shares of LCI in a report on Thursday, August 27 with “Buy” rating.

According to Zacks Investment Research, “Lannett, Inc. manufactures and distributes pharmaceutical products sold under generic names and historically has manufactured and distributed pharmaceutical products sold under its trade or brand names. In addition, the Company contract manufactures and private labels pharmaceutical products for other companies.”

Insitutional Activity: The institutional sentiment increased to 0.88 in Q2 2016. Its up 0.07, from 0.81 in 2016Q1. The ratio improved, as 38 funds sold all Lannett Company, Inc. shares owned while 51 reduced positions. 27 funds bought stakes while 51 increased positions. They now own 27.61 million shares or 4.85% less from 29.01 million shares in 2016Q1.
Prudential Financial holds 0% or 84,688 shares in its portfolio. Perceptive Ltd Liability Corp owns 26,670 shares or 0.04% of their US portfolio. Blackrock Mgmt Ltd last reported 0% of its portfolio in the stock. Schwab Charles Invest Mgmt Incorporated holds 96,485 shares or 0% of its portfolio. D E Shaw Incorporated has invested 0% of its portfolio in Lannett Company, Inc. (NYSE:LCI). Royal Bank Of Canada has invested 0% of its portfolio in Lannett Company, Inc. (NYSE:LCI). Next Finance Group holds 0% of its portfolio in Lannett Company, Inc. (NYSE:LCI) for 300 shares. Thompson Siegel And Walmsley Lc holds 0.34% of its portfolio in Lannett Company, Inc. (NYSE:LCI) for 901,490 shares. Northern Trust holds 0% of its portfolio in Lannett Company, Inc. (NYSE:LCI) for 362,656 shares. Teacher Retirement Systems Of Texas reported 4,101 shares or 0% of all its holdings. The Illinois-based Envestnet Asset Management has invested 0% in Lannett Company, Inc. (NYSE:LCI). Moreover, Blackrock Inc has 0% invested in Lannett Company, Inc. (NYSE:LCI) for 7,517 shares. Susquehanna Llp last reported 0% of its portfolio in the stock. Panagora Asset Management Inc has 7,266 shares for 0% of their US portfolio. Walleye Trading Limited Liability Corp, a Minnesota-based fund reported 200 shares.

Insider Transactions: Since August 31, 2016, the stock had 0 buys, and 3 sales for $416,823 net activity. Landis G. Michael had sold 6,786 shares worth $226,716 on Wednesday, August 31. The insider Maher James M. sold $50,119.

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The company has a market cap of $827.02 million. The Firm makes and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. It has a 18.36 P/E ratio. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.

LCI Company Profile

Lannett Company, Inc., incorporated on December 3, 1991, develops, makes, markets and distributes generic versions of brand pharmaceutical products. The Firm makes and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Firm has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

More news for Lannett Company, Inc. (NYSE:LCI) were recently published by: Fool.com, which released: “Why Lannett Company, Inc. Shares Got Pummeled Today” on October 17, 2016. Prnewswire.com‘s article titled: “Lannett Comments On FDA Proposal Regarding Methylphenidate Extended Release …” and published on October 19, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment